Glaxo's Avandia Risks Prompt Doctors to Switch Drugs

According to Bloomerg.com...
While the study findings raise some concern and indicate the need for more clear data, there is no need for alarm, according to an editorial released today by the Lancet, a prominent medical journal that published one of the largest studies on Avandia.

Doctors, patients and regulators can safely wait for the results of a pivotal trial, dubbed Record, that is specifically looking at heart risks among patients taking Avandia, known chemically as rosiglitazone, the editors said.

Read the full story at Bloomerg.com.

For more breaking news on Diabetes Care, click on Diabetes in the News.